SI
ZYME icon

Stephens Inc’s Zymeworks ZYME Stock Holding History

Stephens Inc’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,882
Closed -$270K – 1290
2023
Q1 		$270K Sell
29,882
-26,765
-47% -$233K 0.01% 921
2022
Q4 		$445K Buy
+56,647
New +$398K 0.01% 737
2020
Q1 		– Sell
-6,097
Closed -$277K – 1217
2019
Q4 		$277K Buy
+6,097
New +$222K 0.01% 899

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Stephens Inc's ZYME Position: Q2 2023 in Review

Stephens Inc sold out of Zymeworks (ZYME) in Q2 2023, closing a stake of 29,882 shares — an estimated $270K sold.

Stephens Inc first reported a position in ZYME in Q4 2019 and held it in 3 quarters. The position peaked at $445K in Q4 2022. 137 funds tracked by Wall St. Rank hold ZYME as of Q2 2023.

  • Stephens Inc reported no remaining Zymeworks position as of Q2 2023 after selling out during the quarter.
  • Stephens Inc sold 29,882 Zymeworks shares in Q2 2023, an estimated $270K.
  • Stephens Inc first reported a position in Zymeworks in Q4 2019 and held it in 3 quarters.
  • Stephens Inc's Zymeworks position peaked at $445K in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Zymeworks as of Q2 2023.

Based on Stephens Inc's 13F filing for Q2 2023, filed 14 Aug 2023.